CN111533659A - Preparation method of acetylsalicylic acid rare earth - Google Patents
Preparation method of acetylsalicylic acid rare earth Download PDFInfo
- Publication number
- CN111533659A CN111533659A CN202010415629.8A CN202010415629A CN111533659A CN 111533659 A CN111533659 A CN 111533659A CN 202010415629 A CN202010415629 A CN 202010415629A CN 111533659 A CN111533659 A CN 111533659A
- Authority
- CN
- China
- Prior art keywords
- rare earth
- acetylsalicylic acid
- preparing
- acid rare
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 47
- 229910052761 rare earth metal Inorganic materials 0.000 title claims abstract description 45
- -1 acetylsalicylic acid rare earth Chemical class 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 150000002910 rare earth metals Chemical class 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims abstract description 15
- 238000001914 filtration Methods 0.000 claims abstract description 13
- 239000002244 precipitate Substances 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000012153 distilled water Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 8
- 239000003513 alkali Substances 0.000 claims abstract description 7
- 239000012266 salt solution Substances 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 12
- 239000000706 filtrate Substances 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000003054 catalyst Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000009967 tasteless effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000012265 solid product Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 150000002500 ions Chemical group 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DKQPTMKDTSKLNF-UHFFFAOYSA-K C(C)O.[Cl-].[Sm+3].[Cl-].[Cl-] Chemical compound C(C)O.[Cl-].[Sm+3].[Cl-].[Cl-] DKQPTMKDTSKLNF-UHFFFAOYSA-K 0.000 description 1
- 150000000703 Cerium Chemical class 0.000 description 1
- 229910004664 Cerium(III) chloride Inorganic materials 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical group [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 208000019667 acute articular rheumatism Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960001759 cerium oxalate Drugs 0.000 description 1
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 1
- ZMZNLKYXLARXFY-UHFFFAOYSA-H cerium(3+);oxalate Chemical compound [Ce+3].[Ce+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O ZMZNLKYXLARXFY-UHFFFAOYSA-H 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- CMDYHTIDHSNRGW-UHFFFAOYSA-L copper;2-acetyloxybenzoate Chemical compound [Cu+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O CMDYHTIDHSNRGW-UHFFFAOYSA-L 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- GAGGCOKRLXYWIV-UHFFFAOYSA-N europium(3+);trinitrate Chemical compound [Eu+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O GAGGCOKRLXYWIV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000012760 heat stabilizer Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- FYDKNKUEBJQCCN-UHFFFAOYSA-N lanthanum(3+);trinitrate Chemical compound [La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FYDKNKUEBJQCCN-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- KUBYTSCYMRPPAG-UHFFFAOYSA-N ytterbium(3+);trinitrate Chemical compound [Yb+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O KUBYTSCYMRPPAG-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- QERFJLRDDKQIKF-UHFFFAOYSA-L zinc;2-acetyloxybenzoate Chemical compound [Zn+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O QERFJLRDDKQIKF-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
Abstract
The invention relates to a preparation method of acetylsalicylic acid rare earth, which comprises the steps of dispersing acetylsalicylic acid in a solvent, dropwise adding a proper amount of alkali solution, controlling the pH value within a specific range, then adding a rare earth salt solution, reacting for a period of time at 60 ℃, generating solid precipitate, washing by distilled water, filtering, and drying at 80 ℃ to obtain a finished product. The advantages are that: the invention can be realized under normal pressure without any catalyst, and has the advantages of low preparation cost, simple and easy synthesis process, safety and reliability. In addition, the filtrate obtained after the reaction of the acetylsalicylic acid and the rare earth salt can be recycled as a solvent, so that the method is green and environment-friendly, and has no any danger or three-waste pollution. Meanwhile, the product has stable chemical property, is nontoxic and tasteless, and is easy for industrial production, storage and transportation.
Description
The technical field is as follows:
the invention relates to a preparation method of acetylsalicylic acid rare earth, belonging to the technical field of rare earth chemical synthesis.
Background art:
acetylsalicylic acid, also known as Aspirin (ASP), is widely used clinically in the treatment of fever, headache, neuralgia, myalgia, rheumatic fever, acute rheumatic arthritis and other diseases. However, with the wide application of aspirin, its adverse reactions are also gradually increasing, mainly manifested in: nausea, vomiting, gastrointestinal discomfort, allergic reaction, liver damage and the like. Therefore, in recent years, its wide application has been greatly limited.
Rare earth is 15 lanthanide elements with atomic numbers from 57-71 in the third subgroup of the periodic table of the elements, and two elements, scandium (Sc) and yttrium (Y), closely related to the lanthanide elements. The application of rare earth in medicines is also widely researched, for example, cerium oxalate can be used for treating marine dizziness and vomiting of pregnancy, inorganic cerium salt can be used as a wound disinfectant, and besides, the rare earth also has the effects of anticoagulation, anti-inflammatory sterilization, anti-arteriosclerosis, anti-tumor and the like.
After the acetylsalicylic acid and the metal ions form a complex, the toxic and side effects of the aspirin can be obviously reduced, and the drug effect and the physiological function of the aspirin are improved. For example, after acetylsalicylic acid and zinc ions form zinc Acetylsalicylate (ASZ), the analgesic effect of the compound is obviously better than that of ASP, and copper acetylsalicylate (CuAsp) has better effects of diminishing inflammation, relieving pain, resisting rheumatism, resisting epilepsy and the like than ASP, and has the advantages of small toxic and side effects and light gastrointestinal adverse reaction. However, most of the acetylsalicylic acid complexes reported so far are concentrated on transition metal ions, and few of the acetylsalicylic acid complexes related to rare earths are reported.
The invention prepares acetylsalicylic acid rare earth with different properties by reacting rare earth ions with acetylsalicylic acid under certain conditions. Research shows that the acetylsalicylic acid rare earth has special effect in the fields of agriculture, fluorescence and the like. For example, the rare earth acetylsalicylic acid has obvious effects of disease resistance induction, early fruiting and yield increase and quality improvement on ginkgo, and a complex formed by the acetylsalicylic acid and a rare earth terbium (Tb) ion has strong green fluorescence. Besides, the rare earth ions have a plurality of 4f and 5d empty electron energy levels, and the 4f and 5d empty electron energy levels can accept lone-pair electrons of 6-12 ligands as coordination center ions. The formed acetylsalicylic acid rare earth can absorb hydrogen chloride generated by PVC decomposition, and has an important effect of slowing down the aging decomposition of PVC resin. Based on the important role of rare earth and acetylsalicylic acid in medicine, the acetylsalicylic acid rare earth also has good prospect in the field of medicine application.
The invention content is as follows:
the invention aims to provide a preparation method of acetylsalicylic acid rare earth.
The invention is implemented by the following technical scheme: a process for preparing the rare-earth acetylsalicylate includes such steps as dispersing acetylsalicylic acid in solvent, adding alkali solution to control pH value to a certain range, adding rare-earth salt solution, reacting at 60 deg.C for a certain time to generate solid deposit, washing with distilled water, filtering and drying at 80 deg.C.
Further, the solvent is one of ethanol, deionized water or acetone.
Further, the alkali is one of sodium hydroxide, potassium hydroxide, sodium bicarbonate or potassium bicarbonate.
Further, the concentration range of the alkali solution is 0.01 mol/L-0.05 mol/L.
Further, the pH value range is 7.5-9.0.
Further, the rare earth salt is nitrate or chloride of rare earth.
Further, the concentration range of the rare earth salt solution is 0.01mol/L-0.1 mol/L.
Further, the reaction time is 0.5-2 h.
The invention has the advantages that:
1. the acetylsalicylic acid rare earth prepared by the invention is reacted under normal pressure, can be realized without any catalyst, and has the advantages of low preparation cost, simple and feasible synthesis process, safety and reliability.
2. The filtrate generated by preparing the acetylsalicylic acid rare earth, namely the filtrate obtained after the reaction of the acetylsalicylic acid and the rare earth salt solution, can be used as a solvent for recycling. Therefore, the invention has no three-waste pollution, is green and environment-friendly and is easy for industrialized production.
3. The product has stable chemical property, no toxicity, no smell and easy storage and transportation. The product has good application prospect in the fields of agriculture, medicine, fluorescence, PVC heat stabilizer and the like.
The specific implementation mode is as follows:
the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
0.54g of acetylsalicylic acid (3mmol) is dissolved in 100ml of aqueous solution, 0.01mol/L aqueous NaOH solution is added to control the pH to 7.5, then 100ml of 0.01mol/L aqueous lanthanum nitrate solution is added, and the mixture is stirred in a beaker at the rotation speed of 200 r/min. Reacting at 60 ℃ for 0.5 hour to generate white precipitate, aging the precipitate for 1 hour, filtering, washing with distilled water for 3 times, filtering, and drying in an oven at 80 ℃ for 4 hours to obtain a white solid product with a yield of 75.4%. The filtrate from the reaction was recovered and supplemented with 15ml of water as solvent, and the reaction was repeated with the other conditions unchanged. The yield of acetylsalicylic acid rare earth is 74.6 percent.
Example 2:
0.54g of acetylsalicylic acid (3mmol) is dissolved in 100ml of ethanol solution, KOH aqueous solution with the concentration of 0.02mol/L is added to control the pH value to be 8.0, then 50ml of cerium trichloride aqueous solution with the concentration of 0.02mol/L is added, and the mixture is stirred in a beaker constantly at the rotating speed of 200 r/min. Reacting at 60 ℃ for 0.5 hour to generate white precipitate, aging the precipitate for 1 hour, filtering, washing with distilled water for 3 times, filtering, and drying in an oven at 80 ℃ for 4 hours to obtain a light yellow solid product with a yield of 78.4%. The filtrate from the reaction was recovered and supplemented with 20ml of ethanol as solvent, and the reaction was repeated with the other conditions unchanged. The yield of the acetylsalicylic acid rare earth is 77.2 percent.
Example 3:
0.54g of acetylsalicylic acid (3mmol) is dissolved in 100ml of aqueous solution, 0.02mol/L aqueous sodium bicarbonate solution is added to control the pH to 8.5, and then 50ml of 0.02mol/L aqueous europium nitrate (1mmol) solution is added, and the mixture is stirred in a beaker at the rotation speed of 200 r/min. Reacting at 60 ℃ for 1 hour to generate white precipitate, aging the precipitate for 1 hour, filtering, washing with distilled water for 3 times, filtering, and drying in an oven at 80 ℃ for 4 hours to obtain a light yellow solid product with a yield of 79.2%. The filtrate from the reaction was recovered and supplemented with 15ml of water as solvent, and the reaction was repeated with the other conditions unchanged. The yield of acetylsalicylic acid rare earth is 78.1 percent.
Example 4:
0.54g of acetylsalicylic acid (3mmol) is dissolved in 100ml of acetone solution, NaOH ethanol solution with the concentration of 0.05mol/L is added, the pH is controlled to be 8.0, then 20ml of samarium trichloride ethanol solution with the concentration of 0.05mol/L is added, and the mixture is stirred continuously in a beaker at the rotating speed of 200 r/min. Reacting at 60 ℃ for 2 hours to generate white precipitate, aging the precipitate for 1 hour, filtering, washing with distilled water for 3 times, filtering, and drying in an oven at 80 ℃ for 4 hours to obtain a light yellow solid product with the yield of 82.2%. The filtrate from the reaction was recovered and supplemented with 25ml of acetone as solvent, and the reaction was repeated with other conditions unchanged. The yield of the acetylsalicylic acid rare earth is 82.4 percent.
Example 5:
0.54g of acetylsalicylic acid (3mmol) is dissolved in 100ml of ethanol solution, potassium bicarbonate aqueous solution with the concentration of 0.05mol/L is added, the pH is controlled to be 9.0, then 20ml of ytterbium nitrate aqueous solution with the concentration of 0.05mol/L is added, and the mixture is stirred continuously in a beaker at the rotating speed of 200 r/min. Reacting at 60 ℃ for 2 hours to generate white precipitate, aging the precipitate for 1 hour, filtering, washing with distilled water for 3 times, filtering, and drying in an oven at 80 ℃ for 4 hours to obtain a white solid product with the yield of 81.6%. The filtrate from the reaction was recovered and supplemented with 20ml of acetone as solvent, and the reaction was repeated with the other conditions unchanged. The yield of the acetylsalicylic acid rare earth is 80.4 percent.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (8)
1. The preparation method of the acetylsalicylic acid rare earth is characterized by comprising the following steps: dispersing acetylsalicylic acid in a solvent, adding an alkali solution to control the pH value to be in a specific range, then adding a rare earth salt solution, reacting for a period of time at 60 ℃, generating solid precipitate, washing by distilled water, filtering, and drying at 80 ℃ to obtain a finished product.
2. The method for preparing the acetylsalicylic acid rare earth as claimed in claim 1, which is characterized in that: the solvent is one of ethanol, deionized water or acetone.
3. The method for preparing the acetylsalicylic acid rare earth as claimed in claim 1, which is characterized in that: the alkali is one of sodium hydroxide, potassium hydroxide, sodium bicarbonate or potassium bicarbonate.
4. The method for preparing the acetylsalicylic acid rare earth as claimed in claim 1, which is characterized in that: the concentration range of the alkali solution is 0.01 mol/L-0.05 mol/L.
5. The method for preparing the acetylsalicylic acid rare earth as claimed in claim 1, which is characterized in that: the pH value range is 7.5-9.0.
6. The method for preparing the acetylsalicylic acid rare earth as claimed in claim 1, which is characterized in that: the rare earth salt is nitrate or chloride of rare earth.
7. The method for preparing the acetylsalicylic acid rare earth as claimed in claim 1, which is characterized in that: the concentration range of the rare earth salt solution is 0.01mol/L-0.1 mol/L.
8. The method for preparing the acetylsalicylic acid rare earth as claimed in claim 1, which is characterized in that: the reaction time is 0.5-2 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010415629.8A CN111533659A (en) | 2020-05-16 | 2020-05-16 | Preparation method of acetylsalicylic acid rare earth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010415629.8A CN111533659A (en) | 2020-05-16 | 2020-05-16 | Preparation method of acetylsalicylic acid rare earth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111533659A true CN111533659A (en) | 2020-08-14 |
Family
ID=71968093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010415629.8A Pending CN111533659A (en) | 2020-05-16 | 2020-05-16 | Preparation method of acetylsalicylic acid rare earth |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111533659A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114249651A (en) * | 2021-12-21 | 2022-03-29 | 包头稀土研究院 | Organic rare earth complex microsphere, preparation method thereof and application of ammonia water |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009292748A (en) * | 2008-06-03 | 2009-12-17 | National Institute Of Advanced Industrial & Technology | Rare earth metal complex, ink composition using the same and fluorescent labeling agent |
| CN103450886A (en) * | 2013-08-20 | 2013-12-18 | 福建师范大学 | Preparation of purple light-excited tri-stimulus composite white light complexes |
| CN104789213A (en) * | 2015-04-21 | 2015-07-22 | 阜阳师范学院 | Rare earth terbium complex and preparation method thereof |
| RU2643966C1 (en) * | 2017-05-29 | 2018-02-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный университет" (ФГБОУ ВО "КубГУ") | Method for obtaining terbium acetylsalicylate (iii) |
-
2020
- 2020-05-16 CN CN202010415629.8A patent/CN111533659A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009292748A (en) * | 2008-06-03 | 2009-12-17 | National Institute Of Advanced Industrial & Technology | Rare earth metal complex, ink composition using the same and fluorescent labeling agent |
| CN103450886A (en) * | 2013-08-20 | 2013-12-18 | 福建师范大学 | Preparation of purple light-excited tri-stimulus composite white light complexes |
| CN104789213A (en) * | 2015-04-21 | 2015-07-22 | 阜阳师范学院 | Rare earth terbium complex and preparation method thereof |
| RU2643966C1 (en) * | 2017-05-29 | 2018-02-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный университет" (ФГБОУ ВО "КубГУ") | Method for obtaining terbium acetylsalicylate (iii) |
Non-Patent Citations (2)
| Title |
|---|
| LIN QIN ET AL.: "PreparationPhoto and Electroluminescence Properties of Novel Rare Earth Aromatic Carboxylates", 《JOURNAL OF RARE EARTHS》 * |
| 霍淑慧 等: "Sm 对阿司匹林的镇痛性能影响", 《稀土》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114249651A (en) * | 2021-12-21 | 2022-03-29 | 包头稀土研究院 | Organic rare earth complex microsphere, preparation method thereof and application of ammonia water |
| CN114249651B (en) * | 2021-12-21 | 2024-04-09 | 包头稀土研究院 | Organic rare earth complex microsphere, preparation method thereof and application of ammonia water |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101486639B (en) | Novel method for synthesizing mixed glucose derivative | |
| CN111533659A (en) | Preparation method of acetylsalicylic acid rare earth | |
| US3916004A (en) | Process for producing dopa preparation | |
| CN110156985A (en) | A kind of high fluidity random copolymerization semi-aromatic nylon and preparation method thereof | |
| CN102190623B (en) | Method for preparing imidazole acetate ionic liquid | |
| CN101362684A (en) | Solution containing vanadium oxalate and preparation method thereof | |
| CN101792463B (en) | Nitrogen-containing aryl hypophosphorous acid metal salt and preparation method thereof | |
| CN102070660B (en) | Synthesis method of rare earth coordination polymer with calcium ion fluorescent probe function | |
| CN109232671B (en) | Ternary rare earth doped polyacid derivative, preparation method thereof and application of polyacid derivative as fluorescent luminescent material | |
| CN101504369B (en) | Bio-luminescent probe molecule intercalation houghite and method for producing the same | |
| EP0247987A1 (en) | A basic metal hydroxysulphate complex in solid form and a method for its manufacture | |
| CN105802604A (en) | Intercalated structure nano material with room-temperature long-afterglow luminescence property and preparation method thereof | |
| CN108659023A (en) | Rare earth with high fluorescence quantum yield-potassium bimetal complexes | |
| CN103044465A (en) | Rare earth coordination polymer microfilm material and method for preparing same | |
| CN105541561A (en) | Method for synthesizing and purifying 1,1,1-tri(4-hydroxy phenyl) ethane | |
| CN112831090A (en) | Preparation method of epoxidized calcium zinc oleate for PVC heat stabilizer | |
| CN111072829A (en) | Method for synthesizing polymaleic acid | |
| US3790625A (en) | Poly(glycidic acid)and methods of preparation therefor | |
| CN1267425C (en) | Method for preparing water soluble azo initiator | |
| CN113402378B (en) | Method for synthesizing 2-chloro-4-fluorobenzoic acid | |
| JP3287562B2 (en) | Method for producing tetraammineplatinum complexes | |
| Lu et al. | Synthesis, structural, and luminescence of two coordination polymers | |
| CN108059596B (en) | Preparation method of high-purity ferric ammonium citrate | |
| CN1359967A (en) | Process for preparing high-Al aluminium citrate cross-linking agent | |
| CN107057703B (en) | Cadmium telluride quantum dot-fibroin and hydrotalcite composite luminescent film and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200814 |
|
| RJ01 | Rejection of invention patent application after publication |